Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.36 |
| ▸ | BRAF | P15056 | 10/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 3/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865671 | 0.91 | ATR (0.38) | RAF1BRAFPIM3ATRCETP | |
| SCHEMBL14865777 | 0.91 | RAF1 (0.39) | RAF1BRAFATR | |
| SCHEMBL14865739 | 0.90 | ATR (0.46) | RAF1BRAFPIM3ATR | |
| SCHEMBL14865610 | 0.87 | ATR (0.41) | RAF1BRAFPIM3ATR | |
| SCHEMBL14866683 | 0.86 | ATR (0.50) | ATR | |
| SCHEMBL14865824 | 0.86 | RAF1 (0.36) | RAF1BRAFPIM3ATRCYP1A2 | |
| SCHEMBL14865705 | 0.85 | ATR (0.36) | RAF1BRAFPIM3ATR | |
| SCHEMBL14865819 | 0.85 | RAF1 (0.44) | RAF1BRAFATRCYP3A4CYP2C9 | |
| SCHEMBL14865750 | 0.84 | RAF1 (0.36) | RAF1BRAFPIM3 | |
| SCHEMBL14865737 | 0.82 | TLR9 (0.36) | RAF1BRAFPIM3TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | RAF1 176/4885BRAF 174/4885PIM3 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.